Trials / Unknown
UnknownNCT05388305
Universal CAR-γδT Cell Injection in the AML Patients
Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Refractory and Relapsed AML Patients
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety of general-purpose CAR-γδT cells in patients with refractory post-transplant relapsed AML.
Detailed description
To evaluate the efficacy and in vivo dynamics of general-purpose CAR-γδT cells in the treatment of refractory relapsed AML patients, and to explore the appropriate therapeutic dose and delivery mode.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAR--γδT cells | Biological: CAR-γδT; Drug: |
Timeline
- Start date
- 2022-04-20
- Primary completion
- 2023-04-30
- Completion
- 2023-05-30
- First posted
- 2022-05-24
- Last updated
- 2022-05-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05388305. Inclusion in this directory is not an endorsement.